The core study duration was approximately 35 weeks per participant (screening: 3 weeks, double-blind treatment period: 24 weeks; follow-up: 8 weeks). Participants who successfully completed the treatment period had the possibility to participate in an optional open-label treatment period with alirocumab 150 mg Q4W until second quarter 2017 or until the drug is commercially available in the country, whatever comes first.